Abstract:Background As a common malignant tumor,prostate cancer(PCa)poses a significant threat to the well-being of men worldwide.The prognosis of PCa is intricately linked to the grade and stage of the tumor at the time of initial detection.Prostate specific antigen(PSA)is a key biomarker for evaluating prostate health,yet lacks specificity for prostate cancer tumors.Elevated PSA levels can also be caused by benign prostate diseases.And the indiscriminate use of biopsy resulting in overdiagnosis.Hence,the development of a prostate cancer risk prediction model based on pre-biopsy clinical indicators in patients can serve as a valuable tool for early screening of individuals with suspicious findings warranting biopsy.Objective To examine the individual risk factors associated with positive prostate biopsy outcomes and develop a risk assessment model for predicting positive biopsy results in PCa screening.Methods A total of 1 138 patients who underwent prostate biopsy in the Department of Urology,the First Affiliated Hospital of Air Force Medical University from January 2011 to June 2023 were gathered and organized.Following the exclusion of 351 cases with inadequate clinical data,the remaining 787 cases were randomly allocated into a training set and validation set in a 7∶3 ratio by R software.Patient demographics and routine biochemical test results prior to biopsy were compiled,with PCa diagnosis determined based on the outcomes of the biopsy.LASSO regression analysis in the R software was utilized to identify independent risk factors associated with the development of PCa based on biochemical indicators.Subsequently,multivariate logistic regression analysis in SPSS software was employed to construct an early screening and predictive model for PCa,with a Nomogram being generated.The model was validated according to the data of training set and validation set.Results The study utilized LASSO regression analysis to identify 6 independent risk factors associated with positive prostate biopsy results,including age,total PSA(tPSA),alkaline phosphatase,serum protein level,Ca2+,and urea.Multivariate Logistic regression analysis revealed that individuals aged 60 years or older(OR=3.769,95%CI=2.393-5.937),with tPSA levels of 10 μg/L or higher(OR=2.259,95%CI=1.419-3.596),and alkaline phosphatase levels exceeding 45 U/L(45-<125 U/L,OR=20.136,95%CI=4.419-91.752;≥125 U/L,OR=45.691,95%CI=9.199-226.951)were at increased risk for positive prostate biopsy outcomes(P<0.05).Conversely,higher levels of serum total protein(≥65 g/L,OR=0.086,95%CI=0.031-0.236),Ca2+(≥2.11 mmol/L,OR=0.148,95%CI=0.054-0.403),and urea(≥9.5 mmol/L,OR=0.069,95%CI=0.019-0.252)were found to be protective factors against positive prostate biopsy results(P<0.05).Based on the identification of 6 independent risk factors exhibiting statistically significant differences,a nomogram was constructed and a predictive model was developed.The predictive model yielded an Area under the receiver operating characteristic(ROC)curve(AUC)of 0.778(95%CI=0.740-0.816)for PCa in the training set,with a sensitivity of 53.2%and a specificity of 85.5%.In the validation cohort,the AUC for PCa was 0.770(95%CI=0.708-0.832),with a sensitivity of 61.2%and a specificity of 80.0%.The goodness of fit test indicated P=0.543 in the training set and P=0.372 in the validation set,demonstrating a satisfactory level of fit.The discriminant analysis(DCA)demonstrated that the high-risk threshold in the training set was below 10%,while in the validation set it was approximately 15%,indicating valuable implications for clinical practice.Conclusion This study developed a PCa nomogram risk prediction model incorporating 6 biochemical indicators,namely age,tPSA,alkaline phosphatase,serum total protein,Ca2+,and urea,prior to prostate biopsy,to effectively forecast PCa risk in patients with favorable early screening outcomes.

Validation Study of a Prostate Health Index-Based Nomogram Model for Predicting Prostate Cancer

Development and external validation of a prostate health index-based nomogram for predicting prostate cancer

The Potential of a Nomogram Combined PI-RADS V2.1 and Contrast-Enhanced Ultrasound (CEUS) to Reduce Unnecessary Biopsies in Prostate Cancer Diagnostics

Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data

Nomograms Combining PHI and PI-RADS in Detecting Prostate Cancer: A Multicenter Prospective Study

Development and validation of a novel nomogram predicting clinically significant prostate cancer in biopsy-naive men based on multi-institutional analysis

Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naive patients with PSA PI-RADS v2.1=3 lesions

Development and Validation of a Prediction Model for Prostate Cancer Early Screening

Development and Validation of a Nomogram Including Lymphocyte-to-Monocyte Ratio for Initial Prostate Biopsy: A Double-Center Retrospective Study

A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer.

Development and External Multicenter Validation of Chinese Prostate Cancer Consortium Prostate Cancer Risk Calculator for Initial Prostate Biopsy.

Development and validation of a nomogram incorporating multi-parametric MRI and hematological indicators for discriminating benign from malignant central prostatic nodules: a retrospective analysis

Predictive value of prostate biopsy results based on predictive model established by the PI-RADS version 2

Development and external validation of a novel nomogram to predict prostate cancer in biopsy‐naïve patients with <scp>PSA</scp> <10 ng/ml and <scp>PI‐RADS</scp> v2.1 = 3 lesions

A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer

[Use of Prostate Health Index in Diagnosing Prostate Cancer in Chinese Men].

The Roles of Prostate-Specific Antigen (PSA) Density, Prostate Volume, and Their Zone-Adjusted Derivatives in Predicting Prostate Cancer in Patients with PSA Less Than 20.0 Ng/ml.

[Development of a Chinese Nomogram Based on Muti-Parametric Magnetic Resonance for Predicting the Probability of Prostate Cancer in Patients after Initial Negative Biopsy].

Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making

Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population.

A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50 ng/ml